These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 186092)

  • 21. Detection of fibrinogen-fibrin degradation products by counterelectrophoresis.
    Brody JI
    J Clin Pathol; 1972 Sep; 25(9):754-6. PubMed ID: 5086217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
    Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
    Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)].
    Klingemann HG; Brunswig D; Liehr H
    Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.
    von Felten A; Straub PW; Frick PG
    N Engl J Med; 1969 Feb; 280(8):405-9. PubMed ID: 4303132
    [No Abstract]   [Full Text] [Related]  

  • 25. Acquired Dysfibrinogenemia Caused by Autoantibody Inhibiting Fibrin Polymerization in a Patient with MELAS Syndrome and Bleeding Tendency.
    Lee N; Kim JE; Yoo HJ; Gu J; Kim H; Chung J; Koh Y; Kim HK
    Ann Clin Lab Sci; 2016 Dec; 46(6):696-700. PubMed ID: 27993886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrin aggregation before sol-gel transition.
    Wiltzius P; Dietler G; Känzig W; Hofmann V; Häberli A; Straub PW
    Biophys J; 1982 May; 38(2):123-32. PubMed ID: 7093417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum apoprotein A-I and A-II levels in liver diseases and cholestasis.
    Fujii S; Koga S; Shono T; Yamamoto K; Ibayashi H
    Clin Chim Acta; 1981 Sep; 115(3):321-31. PubMed ID: 6271423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of fibronectin on fibrinogen conversion into fibrin].
    Litvinov RI; Zubairov DM
    Biokhimiia; 1988 Jul; 53(7):1203-13. PubMed ID: 3179367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Circulating levels of products of fibrinogen and fibrin monomer degradation in liver cirrhosis].
    Rocha E; López Borrasca A
    Rev Med Univ Navarra; 1974; 18(3-4):143-7. PubMed ID: 4471076
    [No Abstract]   [Full Text] [Related]  

  • 32. Evidence for thrombin enhancement of fibrin polymerization that is independent of its catalytic activity.
    Kaminski M; Siebenlist KR; Mosesson MW
    J Lab Clin Med; 1991 Mar; 117(3):218-25. PubMed ID: 2002278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of thrombin and fibrinogen and the polymerization of fibrin monomer.
    Scheraga HA
    Ann N Y Acad Sci; 1983 Jun; 408():330-43. PubMed ID: 6575693
    [No Abstract]   [Full Text] [Related]  

  • 34. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release].
    Soya K; Takezawa Y; Terasawa F; Okumura N
    Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma].
    Lopaciuk S; Snigurowicz J; Rostkowska J; Pniejnia-Olszyński W; Powiertowska-Rezmer M
    Acta Haematol Pol; 1978; 9(3):157-64. PubMed ID: 102100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinogen and dysfibrinogenemia.
    Morse EE
    Ann Clin Lab Sci; 1980; 10(4):351-5. PubMed ID: 7447388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrin formation: the role of the fibrinogen-fibrin monomer complex.
    Brass EP; Forman WB; Edwards RV; Lindan O
    Thromb Haemost; 1976 Aug; 36(1):37-48. PubMed ID: 1036827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of fibrin polymerization inhibitors on quantitative measurements of plasma fibrinogen.
    Hoffman M; Greenberg CS
    Am J Clin Pathol; 1987 Oct; 88(4):490-3. PubMed ID: 3661500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of an inhibitor of the thrombin-fibrinogen reaction localized in rat liver microsomes. Interference with the polymerization step.
    Helgeland L
    Thromb Haemost; 1976 Dec; 36(3):509-16. PubMed ID: 1037148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.